A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer

Lung Cancer

Volumn 32, Issue 3, 2001, Pages 281-287

  Zarogoulidis, K ^a   Kontakiotis, T ^a   Hatziapostolou, P ^a   Fachantidou, E ^a   Delis, D ^a   Goutsikas, J ^a   Constantinidis, T C ^a   Athanasiadis, A ^a   Patakas, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Carboplatin; Chemotherapy; Docetaxel; Non small cell lung cancer (NSCLC)

Indexed keywords

CARBOPLATIN; DOCETAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOXICITY; FEMALE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NEUTROPENIA; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEUTROPENIA; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0035021152     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00226-9     Document Type: Article

References (38)

1. Androulakis N., Kourousis C., Kakolyris S., et al. First line treatment of non-small cell lung cancer with docetaxel and cisplatin. Preliminary results of a phase II study. Ann. Oncol. 7:(Suppl. 5):1996;98-99. abstr. 468P.
2. Belani C.P., Aisner J., Hiponia D., Engstrom C. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin. Oncol. 22:(Suppl. 9):1995;7-12. abstr.
3. Berille J., Le Chevalier T., Zalcberg J.R., et al. Overview of taxotere-cisplatin (TXT/CDDP) combination in non-small lung cancer (NSCLC). Ann. Oncol. 7:(Suppl.):1996;90. abstr.
4. Bizzari JP. Docetaxel PR 56976. Integrated summary. Advanced or metastatic non-small-cell-lung cancer, 16 July 1994 (Data on file, Rhone-Poulenc Rorer).
5. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C., et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 7:1989;1602-1613.
6. Bunn P.A. Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res. 4:1998;1087-1100.
7. Bunn P.A. Jr. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin. Oncol. 16:(Suppl. 6):1989;10-21.
8. Cellerino R., Tummarello D., Guidi F., Raspugli M., Biscottini B., Fatati G. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J. Clin. Oncol. 9:1991;1453-1461.
9. Cerny T., Kaplan K., Pavlidis N., et al. Docetaxel (taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group. Br. J. Cancer. 70:1994;384-387.
10. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III non-small-cell lung cancer. New Engl. J. Med. 323:1990;940-945.
11. Evans W.K. Treatment of NSCLC with chemotherapy is controversial because of low response and high cost. Lung Cancer. Suppl.2:1997;117-118.
12. Finkelstein D.M., Ettinger D.S., Ruckdeschel J.C. Long-term survivors in metastatic nonsmal cell lung cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 4:1986;702-709.
13. Fossella F.V., Lee J.S., Murphy W.K., et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J. Clin. Oncol. 12:1994;1238-1244.
14. Francis P.A., Rigas J.R., Kris M.G., et al. Phase II trial of docetaxel in patients with stage III and IV non-small-lung cancer. J. Clin. Oncol. 12:1994;1232-1237.
15. Ganz P.A., Figlin R.A., Haskell C.M., LaSoto N., Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer. 63:1989;1271-1278.
16. Georgoulias V., Androulakis N., Dimopoulos A.M., et al. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann. Oncol. 9:1998;331-334.
17. Grilli R., Oxman A.D., Julian J.A. Chemotherapy for advanced non-small-cell lung cancer. How much benefit is enough? J. Clin Oncol. 11:1993;1866-1872.
18. Gullen M.H., Woodroffe C.N., Billingharn U., et al. Mitomycin, ifosfarnidc and cisplatin (MIC) in non-small cell lung cancer (NCSLC): 2. Results of a randomized trial in patients with extensive disease. Lung Cancer. 18:(Suppl. 1):1997;5.
19. Hainsworth J.D., Urba W.J., Hon J.K., et al. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small-cell lung cancer: results of a multicentre, phase II trial. Eur. J. Cancer. 34:1998;654-658.
20. lhde D.C., Minna I.D. Non-small-cell- lung cancer. Part I: biology, diagnosis and staging. Curr. Probl. Cancer. 15:1991;61-104.
21. Johnson D.H., Paul D.M., Hande K.R., DeVore R.F. Jr. Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial-LUN-46. Semin. Oncol. 22:(Suppl. 9):1995;30-33.
22. Kaasa S., Lund E., Thorud E., Hatlevoll R., Hést H. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer. 67:1991;2443-2447.
23. Klastersky J. Therapy of non-small-lung cancer. Lung Cancer. 12:(Suppl. 1):1995;S133-S145.
24. Langer C.J., Leighton J.C., Comis R.L., et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J. Clin. Oncol. 13:1995;1860-1870.
25. Laohavinij S., Maoleekoonpairoj S., Cheirsilpa A., et al. Phase II study of paclitaxel and carboplatin for advanced non-small cell lung cancer. Lung Cancer. 26:1999;175-185.
26. Mattson K., Saarinen A., Jekunen A. Combination treatment with docetaxel (taxotere) and platinum compounds for non-small cell lung cancer. Semin. Oncol. 24:(Suppl. 4):1997;5-8.
27. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small-cell lung cancer. Cancer. 75:1995;968-972.
28. Monier A, Douillant JY, Beli L, et al., Interim analysis of a phase II study of docetaxel (taxotere) and cisplatin in advanced non-small-cell lung cancer. Paris, France, Presented at the 6th International Congress on Anti-cancer Treatment, 1998.
29. Mountain C.F. Prognostic implications of the International Staging System for Lung Cancer. Semin. Oncol. 15:(23):1988;236-245.
30. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non small-cell lung cancer. A meta-analysis updated individual patient data from 52 randomized clinical trials. Br Med J 1995;311:899-909.
31. Quoix E., Dietemann A., Charbonneaux J., Boutin C., Meurice J.C., Orlando J.P., Ducolone A., Pauli G., Roegel E. La chernotherapie comportant du cisplatin est-elle utile dans le cancer bronchique non microcellulaire au stade numerique IV. Bull. Cancer (Paris). 78:(4):1991;341-346.
32. Ramanathan R.K., Belani C.P. Chemotherapy for advanced non-small cell lung cancer: past, present and future. Semin. Oncol. 24:1997;440-454.
33. Rapp E., Pater J.L., Willan A., et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer. Report of Canadian multicenter randomized trial. J. Clin. Oncol. 6:1988;633-644.
34. Souquet P.J., Chauvin F., Boisel J.P., et al. Polychernotherapy in advanced non-small-cell lung cancer. A meta analysis. Lancet. 342:1993;19-21.
35. Woods R.L., Williams C.J., Levi J., Page J., Bell D., Byrne M., Kerestes Z.L. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br. J. Cancer. 61:1990;608-611.
36. Zalcberg J.R., Bishop J.F., Millward M.J. Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or localy advanced non-small cell lung cancer (NSCLC). Eur. J. Cancer. 31:(Suppl. 5):1995;1084.
37. Zalcberg J., Millward M., Bishop J., et al. A Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 16:1988;1948-1953.
38. Zarogoulidis K., Papagiannis A., Ziogas E., et al. Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer. Eur. J. Cancer. 3:1997;2428-2431.